Role of physical activity in modulating breast cancer risk as defined by APC and RASSF1A promoter hypermethylation in nonmalignant breast tissue

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 2, 2007, Pages 192-196

  Coyle, Yvonne M ^a   Xie, Xian Jin ^a   Lewis, Cheryl M ^a   Bu, Dawei ^a   Milchgrub, Sara ^b   Euhus, David M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TAMOXIFEN;

ADULT; AGED; BREAST BIOPSY; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METHYLATION; PHYSICAL ACTIVITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

ADULT; BREAST; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DNA METHYLATION; FEMALE; GENES, APC; GENES, RAS; HUMANS; LOGISTIC MODELS; MOTOR ACTIVITY; QUESTIONNAIRES; TUMOR SUPPRESSOR PROTEINS;

EID: 33847696486     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0700     Document Type: Review

References (47)

1. McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? Oncologist 2003;8:326-34.
2. Holmes MD, Chen WY, Feskanich D, Kroenke C, Colditz G. Physical activity and survival after breast cancer diagnosis. JAMA 2005;293:2479-86.
3. Adams SA, Matthews CE, Hebert JR, et al. Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2006;15:1170-8.
4. King M-C, Marks JH, Mandell JB. Breast and ovarian cancer risk due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
5. Hoffman-Goetz L, Apter D, Demark-Wahnefried W, Goran MI, McTiernan A, Reichman ME. Possible mechanisms mediating an association between physical activity and breast cancer. Cancer 1998;83:621-8.
6. McTiernen A, Tworoger SS, Ulrich CM, et al. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized trial. Cancer Res 2004;64:2923-8.
7. Lonning PE, Helle SI, Johhannessen DC, Ekse D, Aldercreutz H. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 1996;39:335-41.
8. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
9. Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-9.
10. Russo J, Hu Y-F, Yang X, Russo IH. Chapter 1: Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr 2000;27:17-37.
11. Klein CB, Costa M. DNA methylation, heterochromatin and epigenetic carcinogens. Mutat Res 1997;386:163-80.
12. Klein CB, Leszczynska J. Estrogen-induced DNA methylation of E-cadherin and p16 in non-tumor breast cells. Proc Am Assoc Cancer Res 2005;46:2744.
13. Fernandez SV, Wu Y-Z, Russo IH, Plass C, Russo J. The role of DNA methylation in estrogen-induced transformation of human breast epithelial cells. Proc Am Assoc Cancer Res 2006;47:1590.
14. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2001;21:5462-82.
15. Li S, Ma L, Chiang TC, et al. Promoter CpG methylation of Hox-a10 and Hox-a11 in mouse uterus not altered upon neonatal diethylstilbestrol exposure. Mol Carcinog 2001;32:213-9.
16. Alworth LC, Howdeshell KL, Ruhlen RL, et al. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. Toxicol Appl Pharmacol 2002;183:10-22.
17. Jin Z, Tamura G, Tsuchiya T, et al. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001;85:69-73.
18. Virmani AK, Rathi A, Sathyanarayana UG, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001;7:1998-2004.
19. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
20. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the CpG island of ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9.
21. Honorio S, Agathanggelou A, Schuermann M, et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003;22:147-50.
22. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 2003;16:1095-101.
23. Fackler MJ, McVeigh M, Mehrotra J, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004;64:4442-52.
24. Lewis CM, Cler LR, Bu D-W, et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005;11:166-72.
25. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
26. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8.
27. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994;86:620-5.
28. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. Model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600-7.
29. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. Model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-66.
30. Sirchia SM, Ren M, Pili R, et al. Endogenous reactivation of the RARβ2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002;62:2455-61.
31. Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinognesis 2006;27:269-77.
32. Friedenreich CM, Courneya KS, Bryant HE. The lifetime total physical activity questionnaire: development and reliability. Med Sci Sports Exerc 1998;30:266-74.
33. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71-80.
34. Key T, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.
35. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 2001;93:1811-7.
36. Carpenter CL, Ross RK, Paganini-Hill A, Bernstein L. Effect of family history, obesity and exercise on breast cancer risk among postmenopausal women. Int J Cancer 2003;106:96-102.
37. Jerónimo C, Costa I, Martins MC, et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003;9:3413-7.
38. Institute of Medicine National Research Council. Fulfilling the potential of cancer prevention and early detection. Washington (DC): The National Academies Press; 2001. p. 64.
39. Rockhill B, Weinberg CR, Newman B. Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. Am J Epidemiol 1998;147:826-33.
40. Kumle M, Weiderpass E, Braaten T, et al. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish women's lifestyle and health cohort study. Cancer Epidemiol Biomarkers Prev 2002;11:1175-81.
41. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
42. Lubin JH, Brinton LA, Blot WJ, et al. Interactions between benign breast disease and other risk factors for breast cancer. J Chron Dis 1983;36:525-31.
43. Friedenreich C, Courneya KS, Bryant HE. Influence of physical activity in different age and life periods on the risk of breast cancer. Epidemiology 2001;12:604-12.
44. Tehard B, Friedenreich CM, Oppert J-M, Clavel-Chapelon F. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev 2006;15:57-64.
45. Thompson HJ. Effect of exercise intensity and duration on the induction of mammary carcinogenesis. Cancer Res 1994;54:1960-3s.
46. Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 1985;45:3415-43.
47. Guler G, Iliopoulos D, Han S-Y, et al. Hypermethylation patterns in the Fhit regulatory region are tissue specific. Mol Carcinog 2005;43:175-81.